Treatment of acromegaly with dopamine agonists

Endocrinol Metab Clin North Am. 1992 Sep;21(3):713-35.


This article reviews the current understanding of how dopamine agonists stimulate growth hormone secretion in normal individuals, yet suppress growth hormone secretion in acromegaly patients. Although bromocriptine normalizes growth hormone or somatomedin C hypersecretion in a minority of patients, a significant number of subjects have a clinical response. Side effects of bromocriptine treatment and newer dopamine agonists are discussed. These drugs can be useful medical therapy, either used alone in selected patients or in combination with other therapeutic modalities.

Publication types

  • Review

MeSH terms

  • Acromegaly / drug therapy*
  • Adenoma / drug therapy
  • Adenoma / pathology
  • Bromocriptine / pharmacology
  • Bromocriptine / therapeutic use
  • Dopamine Agents / pharmacology
  • Dopamine Agents / therapeutic use*
  • Growth Hormone / metabolism
  • Humans
  • Pituitary Gland, Anterior / drug effects
  • Pituitary Neoplasms / drug therapy
  • Pituitary Neoplasms / pathology


  • Dopamine Agents
  • Bromocriptine
  • Growth Hormone